AIM
OCRX

Acrospire Investment Management’s Ocera Therapeutics, Inc. OCRX Stock Holding History

Acrospire Investment Management’s Portfolio OCRX Stock Details OCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-8,268
Closed -$10K – 2013
2017
Q2 		$10K Buy
+8,268
New +$9.61K 0.01% 1813
2017
Q1 		– Sell
-700
Closed -$1K – 2674
2016
Q4 		$1K Buy
+700
New +$1.63K ﹤0.01% 2157

Other funds holding OCRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Acrospire Investment Management's OCRX Position: Q3 2017 in Review

Acrospire Investment Management sold out of Ocera Therapeutics, Inc. (OCRX) in Q3 2017, closing a stake of 8,268 shares — an estimated $10K sold.

Acrospire Investment Management first reported a position in OCRX in Q4 2016 and held it in 2 quarters. The position peaked at $10K in Q2 2017. 21 funds tracked by Wall St. Rank hold OCRX as of Q3 2017.

  • Acrospire Investment Management reported no remaining Ocera Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 8,268 Ocera Therapeutics, Inc. shares in Q3 2017, an estimated $10K.
  • Acrospire Investment Management first reported a position in Ocera Therapeutics, Inc. in Q4 2016 and held it in 2 quarters.
  • Acrospire Investment Management's Ocera Therapeutics, Inc. position peaked at $10K in Q2 2017.
  • 21 funds tracked by Wall St. Rank held Ocera Therapeutics, Inc. as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.